Much of the science and healthcare news during these dire times has been disheartening. But there’s been at least one encouraging development: new COVID-19 vaccines are on track to be the fastest ever to market. And that accelerated pace might become the new normal.
As the COVID-19 pandemic extends its reach worldwide, the demand for available, accurate testing is growing exponentially. Science News reports that COVID-19 testing has been available in limited quantities from the Centers for Disease Control (CDC), but production has not been able to keep up with demand.
QPS Holdings LLC (DE, USA), a global CRO, have announced an access restricted bioanalysis lab that is set up to analyze clinical trial samples for treatments and vaccines to combat the novel coronavirus, COVID-19.
In this infographic commentary, Zamas Lam (QPS) discusses and explains how the oligonucleotide field as changed over the last 2 years.
In this interview, Zamas Lam (QPS; DE, USA) discusses various methods that can be used to quantify oligonucleotide drugs and the progress that has been made to regulate and standardize oligonucleotide analysis in recent years.
We present a rare opportunity to see experts from across the pharmaceutical and CRO industries sharing perspectives on FDA guidance, transitioning skills and future hopes for the bio lab.
Collaboration in action: Nepali chemist receives 10 week bioanalytical training at three Dutch CRO’s
A Chemist and Quality Control Manager from a Nepali pharmaceutical company receives full training in bioanalytical method development and validation.
Find out what Kevin Vernarec (QPS) thinks about how outsourcing might change in the future in this expert interview.
In this interview we talk to John Kolman (QPS, DE, USA) about his hopes for the future of human health care. John highlights the next steps for QPS and how important it is to be adaptive and attentive to new clients and regulations. He also discusses where he think the field will be in 5 years time and the advice he would give to a young scientist.
QPS (DE, USA) is investing in their translational medicine capabilities at its flagship Delaware Technology Park facility.